Enhanced Genomics, a British BioTech company innovating 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has completed a financing round, extending its total Series A funding to €16 million.
Investors in this latest funding are BGF, Parkwalk and Meltwind.
“Our Founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.” said Dietrich A. Stephan, Ph.D., Chair, Enhanced Genomics.
Founded in 2020, Enhanced Genomics claims to be the only BioTech company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential.
Unlocking decades worth of genetic data and providing unparalleled validation via its proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, the Company is able to expedite drug discovery and precision medicine.
Enhanced’s 3D multi-omics platform is the only genome-wide, hypothesis-free technology able to translate massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis. According to the company, this approach supports both target prioritisation, more than doubling the probability of success, and target identification, vastly increasing the number of novel disease targets that can be identified, more efficiently and in a fraction of the time previously possible.
It also allows the stratification of patients into responder groups to improve and accelerate clinical trials.
“This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision,” added Stephan.
The funding will be used to expand Enhanced’s internal therapeutic pipeline in common diseases, including autoimmune conditions such as inflammatory bowel disease. The latest investment will enable the Company to scale its output through strategic partnerships with pharma and biotech, leveraging novel target identification and asset-based opportunities to drive long-term growth.
By translating massive amounts of disease-associated data into actionable insights, Enhanced is identifying high confidence targets with strong genetic evidence of causality, increasing the probability of success in pharmaceutical development, and in a fraction of the time and cost previously possible.
Read the orginal article: https://www.eu-startups.com/2025/09/cambridges-enhanced-genomics-extends-funding-to-e16-million-to-drive-development-of-therapeutics-pipeline/
